About Xvivo Perfusion AB (publ) (XVIPY) β Dividend Analysis 2026
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Is XVIPY a good dividend investment in 2026?
XVIPY offers a 30.58% forward yield with a 50% payout ratio. Strand Safety Score: 60/100 (Moderate Risk). The 5-year dividend CAGR of 0% is modest β investors should weigh current income against growth alternatives.
XVIPY DRIP calculator β what's the difference?
With DRIP on a $10,000 investment over 10 years, your XVIPY portfolio grows to $13.70M vs $10.27M without reinvestment. This is the compound interest effect in action.
XVIPY dividend growth history & forecast
XVIPY has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 30.58%.
FCF ($41M) is below dividends paid ($63M) β risk of cut (FCF: $41M Β· Dividends est.: $63M)
Debt Leverage0.0Γ Debt/EBITDA
30 / 30 pts
30/30
Debt/EBITDA 0.0Γ β low leverage, balance sheet is strong
Earnings Momentum+0.2B β +0.1B β +0.0B
30 / 30 pts
30/30
Net income grew for 2 consecutive years β strong earnings momentum
OVERALL ASSESSMENT
Dividend at moderate risk β monitor coverage and debt closely.
STRAND SCORE
60
/100
Strand Safety Scoreβ’ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
π XVIPY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold XVIPY.
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
π― XVIPY Income Goal & Break-Even
Dividend Break-Even
4yr
Years for dividends to fully repay your XVIPY investment of $6.54/share (πΊπΈ US Taxable (15%) Β· 15.00% tax)
$10K invested Β· 10 Years
Dividends earned (DRIP)
$31.8K
Lost to inflation (2.8% CPI)
β$2.5K
Real purchasing power gain
$29.3K
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in XVIPY for:
Shares needed
14,118
Capital required
$92,332
Monthly income
$2,000
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
π XVIPY Dividend Payment Schedule
XVIPY pays quarterly β 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
π°
Apr
May
Jun
π°
Jul
Aug
Sep
π°
Oct
Nov
Dec
π°
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
π XVIPY vs Healthcare Benchmarks
How XVIPY compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yieldβ²+27.78% vs sectorBetter
XVIPY
30.58%
avg
2.80%
5Y Dividend CAGRβΌ-6.80% vs sectorBelow avg
XVIPY
0.00%
avg
6.80%
Payout Ratioβ²-5.00% vs sectorBetter
XVIPY
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for XVIPY sourced from FMP /financial-growth endpoint β real data, not estimates.
ποΈ XVIPY Insider Activity
No recent SEC filings reported in the last 90 days.
π
Next Earnings Report: 2026-04-22(in 22 days)
π¬
Financial Health Scores
Altman Z-Score
4.87
β Safe Zone β low bankruptcy risk
Safe: >3.0 Β· Grey: 1.81β3.0 Β· Distress: <1.81
Piotroski F-Score
6/9
β οΈ Moderate fundamentals
Strong: 7β9 Β· Moderate: 4β6 Β· Weak: 0β3
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
π About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the XVIPY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β